Clinical studies recruiting near Yulin

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
Phase 3 · The First People's Hospital of Yulin · Tasly Pharmaceutical Group Co., Ltd · NCT07687186 Mobile Applet for Weight Management in Obese Heart Failure Patients
NA · The First Affiliated Hospital of Xi'an Jiaotong University, · Heart Health Research Center · NCT06455878 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · The First Peoples Hospital of Yulin · Amgen · NCT07037433 The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
NA · Research Site · AstraZeneca · NCT06909773 Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds
Phase N/A · Xijing Hospital · NCT05032053 Efficacy and Safety of SR1375 in Adult Patients With CAP
Phase 2 · Yulin First People's Hospital · Shanghai SIMR Biotechnology Co., Ltd. · NCT06577558 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · The First people's hospital of Yulin · DualityBio Inc. · NCT05150691 A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography
Phase N/A · Yulin First People's Hospital · First Hospital of China Medical University · NCT07133516 Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
Phase N/A · Red Cross Hospital of Yulin City · The First Affiliated Hospital of Zhengzhou University · NCT06194968 Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)
Phase 1 · The Second People's Hospital of Yulin · Capital Medical University · NCT07513233 Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploid
Phase 2 · Yulin Red Cross Hospital · Rongrong Liu · NCT06657391 Comparison of a Single Versus Double Perclose Technique for TAVR
NA · Yulin First People's Hospital · Second Affiliated Hospital, Zhejiang University, School of M · NCT06173115 Phase II Study of RC1416 Injection in COPD
Phase 2 · The First People's Hospital of Yulin · Nanjing RegeneCore Biotech Co., Ltd. · NCT07402551 A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events i
Phase N/A · The First Peoples Hospital of Yulin · Amgen · NCT06295679 Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected
Phase N/A · The First People's Hospital of Yulin · First Affiliated Hospital of Guangxi Medical University · NCT07623252 A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe
Phase 3 · Yulin First People's Hospital · Boehringer Ingelheim · NCT07361302 Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
NA · First People People's Hospital of Yulin City · First Affiliated Hospital of Guangxi Medical University · NCT05892354 Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)
NA · Yulin First People's Hospital · Second Affiliated Hospital, Zhejiang University, School of M · NCT05511792 D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell L
Phase 3 · Yulin First People's Hospital · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06300177 Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Phase 2 · Yulin First People's Hospital · Rongrong Liu · NCT07338344 Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With No
Phase 2 · YuLin Red Cross Hospital · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06569524

Look up another city

Look up another condition